Navigation Links
Luoxis Establishes Study Collaborations with Two Research Centers in Oxidative Stress
Date:1/6/2014

GREENWOOD VILLAGE, Colo., Jan. 6, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that subsidiary Luoxis has entered into research agreements with Western Galilee Medical Center (Nahariya, Israel) and the University of Thessaly (Larissa, Greece). These two leading oxidative stress research groups will utilize Luoxis' proprietary RedoxSYS oxidation-reduction potential (ORP) diagnostic system to study oxidative stress markers across hypertension, hemodialysis, sepsis, and physical exertion.

(Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO)

(Logo: http://photos.prnewswire.com/prnh/20130718/MM49747LOGO)

Western Galilee Medical Center, based in Nahariya, Israel, is a leading institution in the study of oxidative stress. Dr. Shifra Sela and Dr. Batya Kristal will serve as the principle investigators studying oxidation-reduction potential in hypertension and hemodialysis.  Both researchers have studied oxidative stress for over 20 years, and their work has been extensively published.

The University of Thessaly, comprising faculties of Medicine, Biochemistry and Biotechnology in Larissa, Greece, is an established institution supported by University Hospital of Larissa and focused on patient care and research, including the study of oxidative stress in critical conditions.  Dr. Maria Karapetsa, Dr. Epaminondas Zakynthinos, Dr. Dimitrios Kouretas, and Dr. Dimitrios Stagos will serve as the principle investigators studying oxidation-reduction potential in sepsis and physical exertion. All researchers have multiple publications to their credit.

"We are pleased to be partnering with Western Galilee Medical Center and the University of Thessaly on these important research projects," said Josh Disbrow, Chief Executive Officer of Luoxis. "Luoxis and these prominent research teams share a strong interest in advancing the study of oxidative stress, and we believe incorporating oxidation-reduction potential measurements into current diagnostic practice will significantly advance assessment of human oxidative stress in prevalent and challenging patient populations."

Both research centers, in collaboration with Dr. David Bar-Or, Ampio and Luoxis Chief Scientific Officer, expect to publish the results of their research in peer-reviewed publications following completion of the studies. 

About the RedoxSYS Diagnostic System
The RedoxSYS diagnostic system is a patented diagnostic device with accompanying disposable sensors that rapidly measures and reports unique oxidative stress parameters by analyzing a single drop of a biologic specimen. Prior to the development of the RedoxSYS diagnostic system, oxidative stress measurement was incomplete, time consuming and impractical in a clinical setting. The RedoxSYS diagnostic system enables robust and rapid assessment of oxidative stress via measurement of oxidation-reduction potential (ORP) in the clinical setting.  ORP is a homeostatic parameter capturing the balance of oxidants and reductants in a biologic system, a complete measure of oxidative stress.  Multiple clinical trials have been completed using the RedoxSYS diagnostic system and have demonstrated the predictive value of ORP across numerous conditions.

About Luoxis
Luoxis is a biotechnology company focused on the development and global commercialization of the RedoxSYS diagnostic system.  The RedoxSYS diagnostic system is comprised of a portable analyzer and disposable sensors that rapidly measure the level of oxidative stress and antioxidant reserves in biologic specimens via assessment of oxidation-reduction potential (ORP). ORP has been shown to be an important measure in both critical and chronic illnesses and is a novel marker of patient morbidity across a wide range of conditions. There are numerous clinical indications for this homeostatic parameter for which there is no currently available test. Luoxis is a majority-owned subsidiary of Ampio Pharmaceuticals, Inc.

About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Forward Looking Statement
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Investor Contact:
Rick Giles
Director of Investor Relations
Ampio Pharmaceuticals, Inc.
Direct: (720) 437-6530
Email: rgiles@ampiopharma.com


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
2. Ampio forms Luoxis Diagnostics to Commercialize ORP Technology
3. Quantum Materials Establishes Milestone as First Company to Deliver Tetrapod Quantum Dot Samples to LCD Display Manufacturer
4. Texas Childrens Hospital establishes the Jeffrey Modell Diagnostic & Research Center with a donation from the Jeffrey Modell Foundation
5. PA Governor Corbett: Americure Rx Establishes Operations in Lehigh Valley; Creates 51 Jobs
6. Winterhawk Consulting Establishes Partnership with Onapsis Inc to expand their SAP security offerings using Onapsis X1.
7. ICV Partners Establishes Dialysis Treatment Platform With Acquisition Of Atlantis Healthcare Group Puerto Rico, Inc.
8. Life Technologies Establishes International Influenza Network
9. H. D. Smith Establishes Specialty Solutions Organization And Realigns Senior Leadership To Support Growing Geographic Reach, Diversified Businesses
10. PQ Bypass Graduates from the Fogarty Institute for Innovation, Establishes Independent Operations
11. HYCOR Establishes Center Of Operations In Kassel, Germany To Provide Dedicated Support To European Distributors And Customers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):